The Filing Desk

Phreesia

PHR · NYSE · Health Care · Financials, fiscal 2018 to 2026

PHR · Last close · November 13, 2026
$12.69
Value Phreesia yourself

Phreesia's revenue rose 14.5% to $481 million in fiscal 2026. Its operating margin was −1.4%, up from −13.8% a year earlier. Free cash flow was $68 million, up 186.1%. The diluted share count rose 6.8%.

Phreesia, Inc. Latest fiscal year ended January 31, 2026 10-K filed March 31, 2026 · 0001412408-26-000079 Updated
Revenue
$481M
14.5%
Operating margin
−1.4%
12.5 pts
Net income
$2M
 
Free cash flow
$68M
186.1%
Return on capital
−2.2%
22.4 pts
Market cap
$793M
Nov 13 close
P/E
74.6x
On $0.17 EPS, 4 qtrs

Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.

Charts show fiscal years, from the 10-K filings.

What Phreesia does

Phreesia sells software and payment tools that doctors' offices and hospitals use to handle patients' visits. Patients use it to find a doctor, book an appointment, check in and fill out forms, and pay, and it follows up after the visit. Its customers are doctors' practices, health systems and hospitals, and also drug companies, government agencies and non-profit groups. In its fiscal year ended January 31, 2026 it says the platform handled about 180 million patient visits, roughly one in six outpatient visits in the United States.

It has three sources of revenue. Subscription and related services are recurring fees from clients. Payment solutions are fees for processing patient payments and for financing. Network Solutions lets drug companies and other organizations reach patients and providers who use Phreesia with messages that follow the rules, usually under annual contracts priced per campaign. Payment revenue is usually higher in the first two to three months of the calendar year, when patient deductibles reset.

In fiscal 2026 Phreesia bought AccessOne, which expands its role in healthcare payments and adds a payment card for providers. It has operations in India. It says it competes with other software companies, including the electronic health record and practice management systems that it connects to.

Its biggest risks, as it describes them

  • Competition from other software companies, including the health record systems it works with.
  • Managing growth and the up-front costs of new client relationships that it may not recover.
  • Privacy concerns, cyberattacks or data breaches involving patient information.
  • Its operations in India, which carry added risks.
  • Revenue that depends on its clients' success and on long, variable sales and set-up cycles.
From Phreesia's annual report on Form 10-K, filed March 31, 2026, in our words; the 10-K has the full description and every risk factor. Updated with each new annual report.

Income statement

Revenue and net income
US$ billions, fiscal years; net losses in red. Revenue on the left axis, net income on the right; zero is the same line on both.
Revenue (left axis)Net income (right axis)
Gross profit, R&D and operating income
US$ billions, fiscal years. Gross profit is revenue minus the cost of what was sold; research and development is one of the costs paid from it; what remains after all operating costs is operating income. Losses in red.
Gross profitResearch and developmentOperating income
Margins
Percent of revenue
GrossOperatingNetFree cash flow
Diluted earnings per share
US$ per share, fiscal years, restated for any stock splits; loss years in red.

Returns on capital

Return on capital and on equity
Percent. Return on capital is after-tax operating income over the money invested in the business (debt plus equity, minus cash); return on equity is net income over shareholders' equity. Both use the average of opening and closing balances.
Return on capitalReturn on equity

Balance sheet

Cash and debt
US$ billions, at each fiscal year end. Debt includes finance leases.
Cash and short-term investmentsDebt
Assets, liabilities and equity
US$ billions, at each fiscal year end. Assets equal liabilities plus equity; negative equity in red.
Total assetsTotal liabilitiesShareholders' equity
Debt and liquidity ratios
Times. Debt to equity, current assets over current liabilities, and net debt over EBITDA (a full year's).
Debt to equityCurrent ratioNet debt to EBITDA

Five years at a glance

Fiscal year endFY22FY23FY24FY25FY26
Cash and short-term investments314177888474
Debt incl. finance leases138121610
Net debt (negative means net cash)−301−169−76−68−64
Net debt to EBITDA————−2.6x
Debt to equity0.0x0.0x0.1x0.1x0.0x
Interest coverage−100.4x−125.1x−73.6x−24.8x−0.9x
Current ratio5.7x3.3x1.8x1.8x1.5x
Quick ratio5.7x3.3x1.8x1.8x1.5x
US$ millions unless stated, at each fiscal year end. Net debt to EBITDA is debt minus cash, divided by operating income before depreciation and amortization: roughly how many years of those earnings the net debt equals. Debt to equity is debt as a multiple of shareholders' equity. Interest coverage is operating income divided by interest expense. The current ratio is current assets over current liabilities; the quick ratio leaves out inventory.

Cash flow

Cash from operations, capital spending and free cash flow
US$ billions, fiscal years. Free cash flow is cash from operations minus capital spending; negative years in red.
Cash from operationsCapital spendingFree cash flow
Stock-based compensation and buybacks
US$ billions, fiscal years. Shares paid to employees (stock-based compensation, a cost that uses no cash) against cash spent buying shares back. Buybacks that only match it leave the share count roughly where it was.
Stock-based compensationShare buybacks
Dividends and buybacks
US$ billions, cash paid in each fiscal year
DividendsShare buybacks
Diluted share count
Weighted-average diluted shares, millions

Projections

Project Phreesia's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.

Insider trades

No officer, director or 10% owner of Phreesia reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.

From Form 4 filings with the SEC. Grants, option exercises and shares withheld for tax aren't counted. Insider trades at all companies

Indicators

Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.

IndicatorFY24FY25FY26
Piotroski F-score2 of 86 of 86 of 8
Rule of 4016.1%23.5%28.6%
Altman Z''−5.28−3.98−1.95
Accruals ratio−28.2%−24.0%−14.5%
Piotroski F-score: how many of nine simple tests of profitability, funding and efficiency the company passed in the year (Piotroski, 2000); 8 or 9 is strong, 0 to 2 weak. Rule of 40: revenue growth plus free cash flow margin; software investors treat 40% or more as the bar. Altman Z'': working capital, retained earnings, operating income and equity weighed against assets and liabilities (Altman, 1995); Altman puts above 2.6 in the safe zone and below 1.1 in the distress zone. Accruals ratio: net income minus cash from operations, over average total assets; lower means profit is backed by cash.

The nine F-score tests

TestFY24FY25FY26
Net income is positiveFailFailPass
Cash from operations is positiveFailPassPass
Return on assets roseFailPassPass
Cash from operations exceeds net incomePassPassPass
Debt fell relative to assetsFailPassPass
Current ratio roseFailPassFail
Share count didn't riseFailFailFail
Gross margin rose———
Revenue rose relative to assetsPassPassPass
F-score2 of 86 of 86 of 8
Companies that report no gross profit are scored on the other eight.

Compare

Put Phreesia side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.

Similar companies

CompanyYearRevenue growthOperating marginFree cash flow marginReturn on capitalNet debt to EBITDAF-scoreCompare
PhreesiaFY2614.5%−1.4%14.1%−2.2%−2.6x6
CertaraFY258.8%5.0%22.6%0.9%1.1x5Compare
Hinge HealthFY2550.6%−92.9%29.0%———Compare
DoximityFY2613.1%33.3%50.6%91.3%−3.3x4Compare
HealthStreamFY254.3%6.7%19.6%———Compare
Each company's latest fiscal year. Fiscal years end in different months, so the periods don't line up exactly. Free cash flow margin is free cash flow as a share of revenue. Net debt to EBITDA is explained under the balance sheet, and the F-score under Indicators.

9 years of figures

Fiscal yearFY18FY19FY20FY21FY22FY23FY24FY25FY26
Income statement
Revenue80100125149213281356420481
Revenue growth—25.1%24.9%19.1%43.4%31.7%26.8%17.8%14.5%
Gross profit—————————
Research and development111419235291112117122
Operating income−15−10−15−26−117−177−136−58−7
Net income−18−15−20−27−118−176−137−582
Diluted EPS (US$)−24.81−24.53−4.50−0.69−2.37−3.36−2.51−1.020.04
Diluted shares (millions)2220405052555862
Cash flow
Cash from operations−11−213−75−90−323279
Capital expenditure757111856911
Free cash flow−18−7−6−8−93−95−382468
Dividends paid000000000
Share buybacks000000000
Acquisitions0106340150153
Stock-based compensation116143659726768
Balance sheet at fiscal year end
Cash and short-term investments10290219314177888474
Debt incl. finance leases—282411138121610
Total assets—59159327494370370388664
Total liabilities—6457637782119124327
Shareholders' equity−168−211102263417288251265337
Margins and ratios
Gross margin—————————
Operating margin−18.2%−9.5%−12.3%−17.3%−54.8%−62.9%−38.3%−13.8%−1.4%
Net margin−22.8%−15.1%−16.3%−18.4%−55.4%−62.7%−38.4%−13.9%0.5%
Free cash flow margin−22.2%−6.9%−5.0%−5.6%−43.7%−33.8%−10.7%5.6%14.1%
Rule of 40 (growth + FCF margin)—18.3%20.0%13.5%−0.2%−2.0%16.1%23.5%28.6%
Return on capital———−44.4%−107.0%−118.3%−73.2%−24.7%−2.2%
Return on equity———−14.9%−34.7%−50.0%−50.8%−22.7%0.8%
Return on assets——−18.6%−11.2%−28.8%−40.8%−37.0%−15.4%0.4%
Net debt to EBITDA—12.6x——————−2.6x
US$ millions unless stated. Where a later 10-K restated a year, the latest filed figure is shown. Download all figures (CSV, US$ millions)
Source: Phreesia's Form 10-K filings, from SEC EDGAR. For information only, not investment advice. The Filing Desk is not affiliated with Phreesia.